Immunohistochemical expression of HIF-1α, IDH1 and TP53: Prognostic profile of Moroccan patients with diffuse glioma

• Published in: Journal of chemical neuroanatomy Vol. 119; p. 102056
• Main Authors: Sfifou, Fatima, Ouzir, Mounir, Hakkou, El Mehdi, Obtel, Majdouline, Errihani, Hassan, Bouzidi, Abderrahmane Al, Abouqal, Redouane, El Ouahabi, Abdessamad, Cherradi, Nadia
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-01-2022
• Subjects: Adult; Brain Neoplasms - genetics; Brain Neoplasms - metabolism; Diffuse gliomas; Female; Glioma - diagnosis; Glioma - metabolism; Glioma - pathology; HIF-1alpha; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; IDH1; Immunohistochemistry; Isocitrate Dehydrogenase - genetics; Isocitrate Dehydrogenase - metabolism; Male; Morocco; Prognosis; TP53; Tumor Suppressor Protein p53 - metabolism; Morocco; Immunohistochemistry; Diffuse gliomas; HIF-1alpha; Hypoxia; TP53; IDH1
• ISSN: 0891-0618; 1873-6300
• DOI: 10.1016/j.jchemneu.2021.102056

Diffuse gliomas are growing brain tumors that occur in adult life. This study was designed to determine whether the immunohistochemical analysis of IDH1, HIF-1alpha, or TP53 can provide useful biomarkers of clinical severity and progression of diffuse gliomas. Also, it is hypothesized that the expression of IDH1 mutant induces HIF-1alpha. Immunohistochemical staining for HIF-1alpha, IDH1, and TP 53 was performed in biopsy or resection (sub-total or gross-total) tissue from diffuse gliomas in a clinical series of 32 patients. Associations of the HIF-1alpha, IDH1, and TP53 with clinical characteristics were evaluated and the co-expression of two biomarkers (HIF-1alpha and IDH1) was tested. Our data revealed that each biomarker is expressed in a subset of gliomas (IDH1 was positive in 56% cases, HIF-1alpha was positive in 50% cases and TP53 was positive in 44% cases). While no associations were found between clinical characteristics and the expression of HIF-1alpha, and TP53, IDH1 expression was associated with less severe clinical presentation (Karnofsky Performance Status) and disease progression and was more often expressed in females than males. In addition, there was no clear association between IDH1 and HIF-1alpha expression (21.9% of patients co-expressed IDH1 and HIF-1alpha). The current series provides clinical and immunohistochemical findings that can be useful for the clinical management of patients with diffused gliomas.
[Display omitted]
•Diffuse gliomas are growing brain tumors that occur in adult life.•The expression of HIF-1α is variable in diffuse glioma, and is an indicator of intra-tumoral hypoxia.•A high expression of HIF-1α is associated with a poor prognosis in diffuse glioma.•The co-expression of HIF-1α and IDH1 can predict disease progression.•It is important to personalise treatment according to the molecular signature of diffuse glioma.